trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'trastuzumab']
standing ovation at #asco2022. plenary session. trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm 
I am a medical oncologist and the Principal Investigator of the American Society of Clinical Oncology TAPUR study. Tweets are my own.